Short description:
Micro-organosphere technologies to guide precision therapy for cancer patients
Drug notes:
Contact us to add description: recruit@workinbiotech.com
Long description:
Xilis is developing next-generation technologies to guide therapies for cancer patients. Current cancer therapies have side effects that could be eliminated if patient-specific responses could be predicted. To overcome this, Xilis is using their MicroOrganoSphere (MOS) technology, which enables patient-derived micro-tumor production. MOS retains unique patient tissue structure, genetic alterations, gene expression and immune microenvironment to enable precision oncology. Having patient predictive tumor models lets Xilis measure cell viability and drug response so that clinicians can make timely decisions for treatment strategies. So far, MOS has worked for breast, lung and liver cancers.
Jobs:
Senior Automation Engineer Durham, NC|2 days ago
Scientist - Immuno-Oncology Durham, NC|2 days ago
Senior / Staff Research Associate (Assay Product D... Durham, NC|27 days ago
Research Associate Durham, NC|28 days ago
Laboratory Technologist Durham, NC|73 days ago
VP, Assay Development Durham, NC|100+ days ago